Metformin and Peripheral Neuropathy: The Hidden Risk of Vitamin B12 Deficiency

Long-term use of the diabetes medication metformin is significantly linked to an increased risk of peripheral neuropathy, driven by the depletion of vitamin B12, according to a systematic review and meta-analysis published in BMC Endocrine Disorders on April 2026. The research analyzed 20 studies encompassing approximately 292,000 adults across 15 countries to establish the quantitative link between the drug and nerve damage.

When the study authors pooled datasets that used consistent diagnostic thresholds, approximately 32.1 percent of patients taking metformin exhibited a vitamin B12 deficiency. That prevalence rate, which translates to nearly one in three treated patients worldwide, appeared with an I² statistical heterogeneity of 0.0 percent, indicating an unusual degree of agreement across the included populations and laboratory methods.

Prevalence of Vitamin B12 Deficiency and Nerve Damage Risk

The quantitative review evaluated multiple study designs to establish the scale of neurological risk among patients with type 2 diabetes. In a pooled analysis of six cross-sectional studies, metformin users demonstrated 84 percent higher odds of peripheral neuropathy compared to non-users, with a pooled odds ratio of 1.84. Longitudinal data reinforced these findings through two separate cohort studies. One reported an adjusted odds ratio of 1.57, while the other documented a hazard ratio of 1.84, indicating that patients on the drug developed neuropathy at nearly twice the rate over time as those not taking it.

The biological mechanism underlying the condition involves cobalamin, an essential micronutrient required for myelin synthesis and maintenance. Metformin interferes with vitamin B12 absorption in the ileum through effects on calcium-dependent membrane processes and gut motility. When B12 levels drop, methylmalonic acid accumulates and degrades the fatty sheath that insulates nerve fibers, producing symptoms such as numbness, tingling, burning pain, and balance difficulties.

Synergistic Vulnerability in Diabetes Patients

The research demonstrated that vitamin B12 deficiency acts as an independent predictor of neuropathy in people with type 2 diabetes. Across four studies specifically pooling diabetes cohorts, deficiency more than doubled the odds of peripheral neuropathy with an odds ratio of 2.09. Researchers noted that this nutritional deficit contributes a measurable share of nerve damage risk that has historically been misattributed entirely to chronic hyperglycemia and microvascular disease.

Data from one cohort study revealed a synergistic effect when multiple risk factors converged. Patients who took metformin while simultaneously experiencing a vitamin B12 deficiency faced a hazard ratio of 5.76 for peripheral neuropathy—representing a nearly six-fold elevation in risk compared to individuals with neither exposure. The authors registered the study protocol prospectively in PROSPERO under registration number CRD420261363992 to prevent outcome switching.

Clinical Screening and Future Monitoring Protocols

Despite the findings, the researchers emphasized that patients should not discontinue metformin, which remains a low-cost, primary glucose-lowering therapy with decades of established safety and cardiovascular benefits. Instead, the authors advocated for routine B12 monitoring and supplementation for individuals on long-term regimens. Oral supplements remain inexpensive and effective, offering a direct mechanism to prevent permanent nerve injury before symptoms manifest.

Uncertainties remain regarding the precise molecular pathways by which metformin alters the gut microbiome and intestinal absorption. Furthermore, cross-sectional designs cannot definitively establish temporality, leaving clinical researchers to rely on prospective observational data while randomized trials of B12 supplementation are pursued to confirm prevention strategies.